PLATO ACT 4: reducing radiotherapy dose in early-stage anal cancer maintains local RFS

18 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Maria Antonietta Gambacorta, MD, Catholic University of the Sacred Heart, Milan, Italy, comments on the results of the PLATO ACT 4 randomized trial evaluating the reduced dose of chemotherapy in patients with early-stage anal cancer. Prof. Gambacorta notes that reducing the dose of radiotherapy from 50 Gray to 41 Gray in 23 fractions did not compromise the local recurrence-free survival rate, which remained above 85%. This interview took place at the ESTRO 2025 congress in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Categoria
Oncology
Commenta per primo questo video.

Prossimo